31 citations
,
October 2019 in “Genes & Diseases” Basal cell carcinomas and squamous cell carcinomas have different gene activity patterns, suggesting unique treatment approaches.
1 citations
,
May 2026 in “Nature Communications” CD19-CAR T cell therapy may help regenerate skin in systemic sclerosis.
March 2026 in “SKIN The Journal of Cutaneous Medicine” All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
12 citations
,
December 2002 in “Archives of Dermatology” Sweet syndrome can be the only sign of hairy cell leukemia relapse.
Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.
3 citations
,
September 2019 in “Clinical and experimental dermatology” Basal cell carcinomas may differentiate similarly to hair follicles and could be influenced by hair cycle-related treatments.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” Targeting specific T cells may help treat alopecia areata.
December 2021 in “Research Square (Research Square)” M-CSF-stimulated myeloid cells can cause alopecia areata in mice.
January 2011 in “Repository KITopen (Karlsruhe Institute of Technology)” Blocking certain proteins on immune cells may help treat alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Patients with cutaneous lupus erythematosus have a higher risk of skin cancer and other cancers.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
28 citations
,
March 2010 in “Histochemistry and Cell Biology” Different markers are found in stem cells of the scalp's hair follicle bulge and the surrounding skin.
2 citations
,
May 2024 in “International Journal of Molecular Sciences” Targeting CD169+ skin macrophages may help treat psoriasis.
28 citations
,
May 2012 in “Experimental Dermatology”
April 2019 in “Journal of Investigative Dermatology” The PROCLIPI study found markers that help predict outcomes in skin lymphoma patients.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
November 2022 in “Journal of Investigative Dermatology” Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.
September 2024 in “Journal of the American Academy of Dermatology” Regulatory γδ T cells help protect hair follicles from alopecia areata and promote hair regrowth.
April 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” CTCF protein is essential for skin and hair follicle development in mice.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.
15 citations
,
August 2006 in “Journal of Cutaneous Pathology” HIV-1 may cause increased stem cell death in hair follicles, leading to hair loss.
January 2024 in “Wiadomości Lekarskie” Enhancing immune response can improve cancer treatment effectiveness.
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
6 citations
,
July 2009 in “Veterinary dermatology” Vesiculobullous lesions should be considered part of canine cutaneous epitheliotropic T-cell lymphoma.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
January 2024 in “Wiadomości Lekarskie” AI can help diagnose Follicular Lymphoma by accurately identifying specific cell types.
January 2026 in “Journal of Investigative Dermatology” Special cells can help regrow hair in alopecia areata.
CMV infection increases the risk of GvHD after bone marrow transplants.